Delayed emesis: Moderately emetogenic chemotherapy (single-day chemotherapy regimens only)

Supportive Care in Cancer

Volumn 19, Issue SUPPL. 1, 2011, Pages

  Roila, Fausto ⁱ   Warr, David ^a   Aapro, Matti ^b   Clark Snow, Rebecca A ^c   Einhorn, Larry ^d   Gralla, Richard J ^e   Herrstedt, Jorn ^f   Saito, Mitsue ^g   Tonato, Maurizio ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d WALTHER CANCER INSTITUTE   (United States)

^e New York Lung Cancer Alliance   (United States)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g JUNTENDO UNIVERSITY HOSPITAL   (Japan)

^h Regional Cancer Center   (Italy)

ⁱ NONE

Author keywords

Delayed emesis; Dopamine receptor antagonists; Moderately emetogenic chemotherapy; Neurokinin antagonists; Serotonin antagonists

Indexed keywords

ANTHRACYCLINE; APREPITANT; CASOPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; EPIRUBICIN; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; LORAZEPAM; METOPIMAZINE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; PROTON PUMP INHIBITOR; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DELAYED EMESIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MODERATELY EMETOGENIC CHEMOTHERAPY; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; NAUSEA; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 79953302387     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-1039-y     Document Type: Article

References (15)

1. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20-28 (Pubitemid 43033835)
2. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932-2947 (Pubitemid 46630595)
3. ASHP (1999) Therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 56(8):729-764
4. Herrstedt J, Roila F (2009) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 20(Suppl 4):156-158
5. NCCN practice guidelines in oncology: antiemesis V.3.2009
6. Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):104-108 (Pubitemid 40558165)
7. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822-2830 (Pubitemid 46179473)
8. Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau Wet al (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113(3):529-535
9. Rapoport BL, Jordan K (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 188 (4):423-431
10. Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S et al (2009) Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27(32):5363-5369
11. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115-124
12. Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL et al (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6(10):765-772 (Pubitemid 41430717)
13. Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S et al (2005) Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 28(3):270-276 (Pubitemid 40800479)
14. Bloch J, Rixe O, Meric JB, Delgado A, Khayat D (2005) Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin 21(11):1763-1771 (Pubitemid 41667243)
15. Khamales S, Bethune-Volters A, Chidiac J, Bensaoula O, Delgado A, Di Palma M (2006) A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. Anticancer Drugs 17(2):217-224